4.6 Article

Gallbladder cancer

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 8, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41572-022-00398-y

关键词

-

资金

  1. Intramural Research Program of the NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics
  2. European Union [825510]
  3. Agencia Nacional de Investigacion y Desarrollo (ANID) [Fondecyt 1221345]
  4. Millennium Science Initiative Program: Millennium Institute on Immunology and Immunotherapy [ICN09_016/ICN 2021_045, P09/016-F]

向作者/读者索取更多资源

Gallbladder cancer is the most common cancer of the biliary tract and often has a poor prognosis. Early detection is challenging and chronic inflammation plays a significant role in the development of this cancer. Surgical resection is the main curative treatment option, but it is only suitable for a small number of cases.
Gallbladder cancer is the most common cancer of the biliary tract and often has a very poor prognosis. This Primer by Roa and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of gallbladder cancer, and discusses patient quality of life and open research questions for this disease. Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour and limited therapeutic options. Early detection at a curable stage remains challenging because patients rarely exhibit symptoms; indeed, most GBCs are discovered incidentally following cholecystectomy for symptomatic gallbladder stones. Long-standing chronic inflammation is an important driver of GBC, regardless of the lithiasic or non-lithiasic origin. Advances in omics technologies have provided a deeper understanding of GBC pathogenesis, uncovering mechanisms associated with inflammation-driven tumour initiation and progression. Surgical resection is the only treatment with curative intent for GBC but very few cases are suitable for resection and most adjuvant therapy has a very low response rate. Several unmet clinical needs require to be addressed to improve GBC management, including discovery and validation of reliable biomarkers for screening, therapy selection and prognosis. Standardization of preneoplastic and neoplastic lesion nomenclature, as well as surgical specimen processing and sampling, now provides reproducible and comparable research data that provide a basis for identifying and implementing early detection strategies and improving drug discovery. Advances in the understanding of next-generation sequencing, multidisciplinary care for GBC, neoadjuvant and adjuvant strategies, and novel systemic therapies including chemotherapy and immunotherapies are gradually changing the treatment paradigm and prognosis of this recalcitrant cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据